Transcutaneous Electrical Nerve Stimulation for the Long-Term Treatment of Ocular Pain.
Chronic ocular pain
chronic pain
neuropathic pain
pain management
transcutaneous electrical nerve stimulation
Journal
Neuromodulation : journal of the International Neuromodulation Society
ISSN: 1525-1403
Titre abrégé: Neuromodulation
Pays: United States
ID NLM: 9804159
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
06
09
2019
revised:
13
02
2020
accepted:
24
02
2020
pubmed:
21
3
2020
medline:
16
7
2021
entrez:
21
3
2020
Statut:
ppublish
Résumé
Ocular pain is a debilitating condition that is challenging to treat as therapies that target the ocular surface are often ineffective. We previously reported a short-term reduction in ocular pain after one periocular transcutaneous electrical nerve stimulation (TENS) session. The current study aims to elucidate the long-term effect of TENS on ocular pain. Fourteen individuals with eye pain were identified as candidates for a TENS device (RS Medical, Vancouver) for home use after a successful trial in clinic between February 2018 and July 2019 at the Miami Veterans Administration Hospital or University of Miami. Ten of the 14 patients were included in this retrospective review, based on the inclusion of receiving and using the device for a minimum of three months. The median age of the ten patients was 47.5 years, range 32-73 years, and eight were male. The main outcome measures were 1) frequency of long-term integration of TENS into ocular pain management and 2) patient reported ocular pain intensity (0-10) pre- vs. post-treatment. Patients reported an initial median use of the device 14.0 times per week and over time reducing the frequency to 3.0 times per week. All reported that the TENS unit was successfully incorporated into their ocular pain management routine for at least three months (median duration of use 6.5 months, range 3-14 months). Nine of ten patients reported subjective pain reduction with use of the TENS device at home. Overall, pain intensity decreased by approximately 27.4% (mean rank = 5.6, Z = -2.1, p = 0.02) post- vs. pre-treatment. No adverse events associated with TENS were reported in any patient. Our preliminary data suggest that TENS can be integrated into the long-term management of ocular pain with improvements in overall pain intensity.
Identifiants
pubmed: 32196838
doi: 10.1111/ner.13146
pmc: PMC7483841
mid: NIHMS1577679
pii: S1094-7159(21)00252-X
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
871-877Subventions
Organisme : NEI NIH HHS
ID : R01 EY026174
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY014801
Pays : United States
Organisme : Research to Prevent Blindness Unrestricted Grant
Organisme : NIH Center Core Grant
ID : P30EY014801
Organisme : Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research
ID : EPID-006-15S (Dr. Galor)
Organisme : CSRD VA
ID : I01 CX001089
Pays : United States
Organisme : CSRD VA
ID : I01 CX002015
Pays : United States
Organisme : Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research
ID : R01EY026174 (Dr. Galor)
Informations de copyright
© 2020 International Neuromodulation Society.
Références
Ocul Surf. 2018 Jan;16(1):31-44
pubmed: 29031645
Am J Ophthalmol. 2003 Aug;136(2):318-26
pubmed: 12888056
Am J Ophthalmol. 2019 Jun;202:47-54
pubmed: 30721689
Auton Neurosci. 2014 May;182:102-7
pubmed: 24411269
Cephalalgia. 2019 Jan;39(1):3-14
pubmed: 30449151
Ophthalmic Surg. 1991 Aug;22(8):462-6
pubmed: 1717913
Ocul Surf. 2017 Apr;15(2):193-201
pubmed: 28042094
Clin Investig (Lond). 2015;5(3):267-285
pubmed: 25960865
Ocul Surf. 2012 Jan;10(1):2-14
pubmed: 22330055
J Pain Res. 2018 Apr 09;11:703-714
pubmed: 29670397
Acta Neurol Scand. 2019 Mar;139(3):276-283
pubmed: 30428122
Pain Med. 2016 Apr;17(4):746-55
pubmed: 26814296
J Headache Pain. 2018 May 29;19(1):42
pubmed: 29845369
Br J Ophthalmol. 2015 May;99(5):665-8
pubmed: 25336572
Neuropharmacology. 2003 Dec;45(8):1111-9
pubmed: 14614954
PLoS One. 2016 Dec 2;11(12):e0167476
pubmed: 27911934
Br J Sports Med. 1990 Jun;24(2):87-92
pubmed: 1702337
J Pain Res. 2019 Feb 25;12:743-752
pubmed: 30881088
Can J Neurol Sci. 2015 Mar;42(2):125-31
pubmed: 25804249
J Pharmacol Exp Ther. 2001 Jul;298(1):257-63
pubmed: 11408550
Anesthesiology. 2005 Aug;103(2):221-3
pubmed: 16052101
Brain Res. 2007 Mar 9;1136(1):43-50
pubmed: 17234163
J Appl Oral Sci. 2017 Mar-Apr;25(2):112-120
pubmed: 28403351
J Craniomaxillofac Surg. 1988 Nov;16(8):379-81
pubmed: 3264557
Eye Contact Lens. 2017 Jul;43(4):213-217
pubmed: 27243349
Dent Res J (Isfahan). 2014 Nov;11(6):676-9
pubmed: 25540662
Neurology. 2013 Feb 19;80(8):697-704
pubmed: 23390177
Neuromodulation. 2018 Dec;21(8):727-734
pubmed: 29283468
Pain. 2003 Sep;105(1-2):205-13
pubmed: 14499437
Medicine (Baltimore). 2018 Jun;97(26):e11080
pubmed: 29952946
J Comp Neurol. 2005 Dec 26;493(4):510-23
pubmed: 16304628
Am J Ophthalmol. 2012 Jun;153(6):1061-66.e3
pubmed: 22330309
Clin Ophthalmol. 2018 Jan 15;12:125-139
pubmed: 29391773
Neurol Sci. 2018 Jun;39(Suppl 1):163-164
pubmed: 29904846
Front Neurol. 2017 Jun 15;8:282
pubmed: 28663737
Arch Ophthalmol. 2000 Sep;118(9):1264-8
pubmed: 10980773
Arch Ophthalmol. 2009 Jun;127(6):763-8
pubmed: 19506195
Ocul Surf. 2016 Jul;14(3):365-76
pubmed: 27224876
J Neurosci Rural Pract. 2011 Jul;2(2):150-2
pubmed: 21897677
J Chem Neuroanat. 2012 Mar;43(2):103-11
pubmed: 22119519
Science. 1965 Nov 19;150(3699):971-9
pubmed: 5320816
J Pain. 2005 Oct;6(10):673-80
pubmed: 16202960